Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

Natera Reports Second Quarter 2026 Financial Results

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera, Inc. reported strong financial results for Q2 2026, with total revenues reaching $752.8 million, marking a 37.7% increase compared to the same quarter in 2025. The company's gross margin also improved, rising to 64.5%. These results highlight Natera's ongoing leadership in the field of cell-free DNA and genetic testing.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenues increased by 37.7% year-over-year.
  • Gross margin improved from 63.4% to 64.5%.
  • Natera continues to lead in cell-free DNA and genetic testing.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Recent Financial Highlights Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. Generated a gross margin1 of 64.5% in the second quarter of 2026, compared to a gross margin1 of 63.4% in the second quar

Frequently Asked Questions

What were Natera's total revenues for Q2 2026?

Natera generated total revenues of $752.8 million in Q2 2026.

How much did Natera's revenue increase compared to Q2 2025?

Natera's revenue increased by 37.7% compared to Q2 2025.

What was Natera's gross margin in Q2 2026?

Natera's gross margin was 64.5% in Q2 2026.

What is Natera known for?

Natera is a global leader in cell-free DNA and genetic testing.

ShareAdd on Google
Tags: NTRA Viatris Investor Conferences Healthcare Natera financial results cell-free DNA genetic testing
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$1088M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AtezolizumabPhase 3
Muscle-invasive Bladder Cancer →